This is a commentary on AI development, not a concrete new development, therefore it is not eligible for signal extraction.
This collaboration could unlock new treatment paradigms for advanced solid tumors by combining SHP2 and MEK inhibitors. Success in these trials may lead to more effective combination therapies, potentially addressing unmet needs in oncology and strengthening AstraZeneca's position in the precision medicine market.
AstraZeneca and Jacobio are collaborating on a clinical trial for advanced solid tumors.
The trial will test the combination of Jacobio's SHP2 inhibitor (JAB-3312) and AstraZeneca's MEK inhibitor (selumetinib).
The partnership includes a clinical trial collaboration and a supply agreement.
Jacobio Pharma, a prominent Chinese biotech, brings significant APAC relevance to this partnership. The collaboration offers AstraZeneca a strategic entry point into the vast and growing oncology markets across China and other key APAC regions like Japan and South Korea, where cancer prevalence is high. This could accelerate patient recruitment for trials and future commercialization efforts, intensifying competition for local oncology players.
The trial will test the combination of Jacobio's SHP2 inhibitor (JAB-3312) and AstraZeneca's MEK inhibitor (selumetinib).
AstraZeneca and Jacobio are collaborating on a clinical trial for advanced solid tumors.
Sign in to save notes on signals.
Sign In